Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 193.4% in December

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 650,544 shares, an increase of 193.4% from the November 30th total of 221,699 shares. Based on an average daily volume of 933,057 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.8% of the company’s stock are sold short. Approximately 0.8% of the company’s stock are sold short. Based on an average daily volume of 933,057 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CTOR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Oncology in a report on Monday. Maxim Group upgraded Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research note on Tuesday, September 23rd. Finally, Citigroup upgraded Citius Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, September 23rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Citius Oncology presently has an average rating of “Hold” and an average target price of $6.00.

Citius Oncology Stock Down 1.3%

Shares of NASDAQ:CTOR traded down $0.02 during trading hours on Friday, reaching $1.13. The stock had a trading volume of 414,206 shares, compared to its average volume of 861,394. Citius Oncology has a 1 year low of $0.55 and a 1 year high of $6.19. The firm’s 50 day moving average is $1.35 and its 200-day moving average is $1.89. The stock has a market capitalization of $95.82 million, a price-to-earnings ratio of -3.32 and a beta of 2.98. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.02 and a current ratio of 0.56.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings data on Tuesday, December 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).

Hedge Funds Weigh In On Citius Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTOR. Citadel Advisors LLC acquired a new position in shares of Citius Oncology in the 3rd quarter valued at $36,000. Bank of America Corp DE boosted its stake in Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after acquiring an additional 8,411 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in Citius Oncology in the second quarter valued at $51,000. IFP Advisors Inc grew its holdings in shares of Citius Oncology by 49.5% during the third quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock worth $67,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Citius Oncology by 179.0% during the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after purchasing an additional 36,758 shares in the last quarter. 70.52% of the stock is owned by institutional investors and hedge funds.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.